DAEWOONG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,400 KRW | -1.97% |
|
-7.79% | -15.74% |
| Mar. 08 | Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 15 | Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia | MT |
| Sales 2024 * | 1,883B 1.37B | Sales 2025 * | 2,082B 1.52B | Capitalization | 711B 518M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.48 x |
| Net Debt 2024 * | 199B 145M | Net Debt 2025 * | 112B 81.83M | EV / Sales 2025 * | 0.4 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 348 |
| Yield 2024 * |
0.57% | Yield 2025 * |
0.57% | Free-Float | 31.92% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -1.97% | ||
| 1 week | -7.79% | ||
| Current month | -13.86% | ||
| 1 month | -10.54% | ||
| 3 months | -12.83% | ||
| 6 months | +6.49% | ||
| Current year | -15.74% |
1 week
17 400.00
18 690.00
1 month
17 400.0022 350.00
Current year
17 400.0027 100.00
1 year
11 460.0027 100.00
3 years
11 460.0049 550.00
5 years
6 470.0086 700.00
10 years
6 470.0086 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Chun Yoon
CEO | Chief Executive Officer | 64 | 85-07-31 |
Chang-Jae Lee
BRD | Director/Board Member | 47 | 02-11-30 |
Woo-Bang Jeon
AUD | Comptroller/Controller/Auditor | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Cheol Kang
BRD | Director/Board Member | 67 | 22-03-28 |
Jae-Chun Yoon
CEO | Chief Executive Officer | 64 | 85-07-31 |
Geon-Haeng Lee
BRD | Director/Board Member | 63 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 17,400 | -1.97% | 39,840 |
| 24-04-16 | 17,750 | -3.01% | 59,075 |
| 24-04-15 | 18,300 | -0.54% | 37,088 |
| 24-04-12 | 18,400 | -1.23% | 31,319 |
| 24-04-11 | 18,630 | -1.27% | 75,412 |
End-of-day quote Korea S.E., April 16, 2024
More quotes
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
17,400
KRW
Average target price
25,000
KRW
Spread / Average Target
+43.68%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.74% | 514M | |
| +20.29% | 44.1B | |
| +17.11% | 21.97B | |
| +8.36% | 13.27B | |
| +7.10% | 13.22B | |
| +36.34% | 11.36B | |
| -8.53% | 7.07B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.09% | 5.23B |
- Stock Market
- Equities
- A003090 Stock
